Wyeth

American Cyanamid Company

Janssen Sciences Ireland Uc

Janssen Alzheimer Immunotherapy

American Home Products Corporation

Jack Steven Jacobsen

Michael Peter Vitek

Jonathan A Bard

Eileen Marie Kajkowski

Heidi Sofia

Bradley A Ozenberger

Stephen G Walker

Lioudmila Tchistiakova

Davinder Gill

James Callaway

Angela Widom

David S Howland

Guriq Basi

Ivan Lieberburg

Michael Grundman

Lars Ekman

Keith M Gregg

Ronald Black

Wagner Marcelo Zago

Manuel J Buttini

Gene G Kinney

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Immunotherapy regimes dependent on ApoE status

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Use of tau to monitor immunotherapy

The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (A&#x3b2;). Preferred agents include antibodies, e.g., humanized antibodies specific for A&#x3b2;.

Humanized A&#x3b2; antibodies for use in improving cognition

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&#x3b2; in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.

Humanized antibodies that recognize beta amyloid peptide

Novel proteins which bind human &#x3b2;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.

&#x3b2;-amyloid peptide-binding proteins and polynucleotides encoding the same

Novel proteins which bind human &#x3b2;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided.

Novel proteins which bind human &bgr;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.

&bgr;-amyloid peptide-binding proteins and polynucleotides encoding the same

This application describes a purified and isolated fragment of a nucleic acid molecule encoding an amyloid precursor mutein, wherein the fragment comprises a nucleic acid sequence encoding at least one marker and a nucleic acid sequence of about 419, about 475 or about 494 amino acid residues in which a portion thereof encodes a .beta.-amyloid protein domain. Also described is a method for screening for a compound which reduces the formation of .beta.-amyloid protein.

Amyloid precursor proteins and method of using same to assess agents

This disclosure concerns a method of detecting the presence of a polypeptide in a sample wherein the polypeptide is encoded by a fragment of a nucleic acid molecule encoding an amyloid precursor mutein and the fragment comprises a sequence encoding at least one marker and a sequence encoding about 419 amino acid residues of the APP-695 isoform, about 475 amino acid residues of the APP-751 isoform or about 494 amino acid residues of the APP-770 isoform. The method encompasses contacting the sample with an antibody, which specifically binds the marker or the amyloid precursor mutein, under suitable conditions to favor the formation of an antibody-antigen complex and detecting the presence of any complex thus formed. The disclosure also deals with the method employing the above nucleic acid fragment wherein the amino acid residues from position 11 to position 28 are deleted from the portion of the sequence encoding the .beta.-amyloid protein domain and in which an alanine substitution at a phosphorylation site within the cytoplasmic domain of the amyloid precursor protein is encoded.

Growing community of inventors

Ramsey, NJ, United States of America

Jack Steven Jacobsen